Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
about
The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor functionMesothelin targeted cancer immunotherapySoluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaStromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cellsChimeric antigen receptor T-cell therapy for solid tumorsAdvances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinIdentification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatusA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.Improving antibody affinity by mimicking somatic hypermutation in vitro.Preparation of single chain variable fragment of MG(7) mAb by phage display technology.Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus.Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.A novel high-affinity human monoclonal antibody to mesothelin.Discovery of mesothelin and exploiting it as a target for immunotherapy.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.Novel systemic therapy against malignant pleural mesothelioma.Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.Investigational approaches for mesothelioma.Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.Recombinant immunotoxins for cancer therapy.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigenRedirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptorMesothelin-targeted agents in clinical trials and in preclinical development.scFv antibody: principles and clinical applicationFurin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Chicken scFvs with an Artificial Cysteine for Site-Directed ConjugationA recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityOptimization of Gene Transfection in Murine Myeloma Cell Lines using Different Transfection Reagents.The role of mesothelin in tumor progression and targeted therapy.Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biologyTargeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing
P2860
Q24554278-7A6BE863-7131-4E02-BB38-FF39BF19A8A7Q24656242-9BE0F0EF-3365-43C6-845A-B968C9407C8DQ24685080-EF21CAC8-2486-47D6-B96F-D8DA85D932C7Q24797540-DDABD21E-F96B-4C88-AC40-334497930D4BQ26750908-CE863D7E-3097-4A51-81B7-F4110B4DFA4DQ27015134-CBA21D3A-B2AD-4A5F-9850-EB27570313DFQ28752041-6EA8F51A-8730-4E15-BCC0-35470F7D4BD9Q30478956-27733EED-56B7-4421-B1DA-832253FA6546Q30711622-7B710092-FB2C-4E71-8D44-6C257569B027Q30724948-24A68FCE-DA69-48CE-8F15-8634E409D6D9Q30803706-0FB7AEBE-1401-49EE-8722-860592124195Q31915221-217C5450-F4EA-4D70-A60E-1B509A38357DQ32028600-8E5EA7C7-7A34-4ED3-8B7A-DCE4B41AF259Q33297414-132C2F86-CAEA-48A9-A5A0-4657C051D481Q33634221-11766723-3A28-4CC9-80EA-35C0C387D8E1Q33772688-8C5A36BE-E7DF-400F-B28B-A01B064C193BQ33816551-6B02F0CD-5CEA-431B-A376-59101EBF5EECQ33828838-825A3A9C-2993-4285-AA21-301830996F87Q33890499-1C926169-DEF4-4CB7-B9CE-0B5B3A6BC9D7Q34050438-413E8B0F-762B-40DF-A1BB-0E2BED45956DQ34111770-F69F681B-6956-44DF-B6C2-DA673C6BCED5Q34293068-6EBF7BF7-9AC0-463F-A855-C1124ED01E86Q34313298-3F312843-FF44-4050-8889-178AAD99AE6AQ34451921-C889588B-F52A-498B-97E4-A70400579F22Q34676443-CD8C187E-9257-4C83-85BE-24C3864E26EBQ34834369-13DBB079-03BC-47CD-A138-96F7605C84DBQ35023967-F8868CE9-9161-4023-9E04-0B53764D743BQ35049589-4CCD2554-07AB-44F4-88E9-3D454D34EFF4Q35746649-52157231-E44C-4CD7-80F3-5F6708F78F94Q35802193-44ABBC4C-6057-4082-8E0A-8C691F8A544BQ35815380-57C2C76A-0135-48E1-A48A-84D5455E058DQ35852647-015F05A4-A9B7-4186-A608-6289AAE1B36AQ35984815-E82B11CF-8A11-41B3-98F2-F5247E9827ADQ36359728-AF50085E-4773-406A-819C-FFA3B0683C50Q36463396-2C74CCE1-0E6C-4806-8A4F-EBB2D5535880Q36536466-09046F7B-9511-4AF2-B097-497354D9B6D6Q36571310-E289D89F-4323-45EC-BDA9-E4DB25A78F50Q36597831-8B41C6F5-34AC-4E95-B0C9-E6F28C8B77BDQ36645343-296AB733-79FD-4B25-8E68-E10EFE0861EBQ36659265-1A4F3533-606D-4E5D-BCDF-2F7B9FC1298A
P2860
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@ast
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@en
type
label
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@ast
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@en
prefLabel
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@ast
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@en
P2093
P2860
P356
P1476
Isolation of a high-affinity s ...... oxin with anti-tumor activity.
@en
P2093
P2860
P304
P356
10.1073/PNAS.95.2.669
P407
P577
1998-01-01T00:00:00Z